UCGI 25: A multicentric randomized phase II trial evaluating dual targeting of the epidermal growth factor (EGFR) using the combination of cetuximab and afatinib versus cetuximab alone in patients (pts) wih chemotherapy refractory wtRAS metastatic colorectal cancer (mCRC).
Hélène Senellart
No relevant relationships to disclose
Emmanuelle Samalin
No relevant relationships to disclose
Antoine Adenis
Consultant or Advisory Role - Bayer; Roche; Sanofi
Honoraria - Bayer; Sanofi
Research Funding - Bayer; Sanofi
Other Remuneration - Amgen; Roche
David Malka
Consultant or Advisory Role - Boehringer Ingelheim
Eric Francois
No relevant relationships to disclose
Christelle De La Fouchardiere
Honoraria - Merck Serono
Eveline Boucher
No relevant relationships to disclose
Astrid Lievre
No relevant relationships to disclose
Trevor Stanbury
No relevant relationships to disclose
Jaafar Bennouna
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim